Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$5.904M
TTM
Current Assets
Q4 2024
Current Liabilities
Current Ratio
Total Assets
Q4 2024
Total Liabilities
Q4 2024
Book Value
$3.753M
Q4 2024
Cash
Q4 2024
P/E
-0.9021
Nov 29, 2024 EST
Free Cash Flow
-$4.604M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2024 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2024 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2024 2023 2022 2021 2020 2019
Selling, General & Admin $3.483M $7.425M $7.118M $3.641M $3.355M $1.309M
YoY Change -53.09% 4.3% 95.49% 8.54% 156.32%
% of Gross Profit
Research & Development $6.455M $7.446M $5.201M $1.311M $1.069M $3.700M
YoY Change -13.31% 43.15% 296.83% 22.56% -71.1%
% of Gross Profit
Depreciation & Amortization $50.74K $23.07K $3.549K $0.00
YoY Change 119.94% 550.04%
% of Gross Profit
Operating Expenses $9.938M $14.87M $5.201M $1.311M $4.424M $5.009M
YoY Change -33.17% 185.9% 296.83% -70.37% -11.67%
Operating Profit -$9.938M -$14.87M -$12.32M -$4.952M
YoY Change -33.17% 20.71% 148.78%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2024 2023 2022 2021 2020 2019
Interest Expense $10.10K -$7.700K $46.52K $142.4K $13.93K $146.4K
YoY Change -231.18% -116.55% -67.33% 922.4% -90.48%
% of Operating Profit
Other Income/Expense, Net -$10.10K -$7.701K -$42.52K -$94.68K
YoY Change 31.16% -81.89% -55.09%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2024 2023 2022 2021 2020 2019
Pretax Income -$9.948M -$14.88M -$12.36M -$5.047M -$4.410M -$4.863M
YoY Change -33.14% 20.35% 144.96% 14.43% -9.3%
Income Tax
% Of Pretax Income
Net Earnings -$9.948M -$14.88M -$12.36M -$5.047M -$4.410M -$4.863M
YoY Change -33.14% 20.35% 144.96% 14.43% -9.3%
Net Earnings / Revenue
Basic Earnings Per Share -$14.70 -$0.15 -$0.14
Diluted Earnings Per Share -$14.70 -$0.15 -$138.8K -$59.42K -$51.93K -$57.25K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2024 2023 2022 2021 2020 2019
Cash & Short-Term Investments $376.1K $5.141M $14.06M $1.929M $90.29K $42.61K
YoY Change -92.69% -63.45% 628.97% 2036.75% 111.9%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets $79.19K $694.9K $349.7K $967.1K $1.529M $1.173M
YoY Change -88.6% 98.71% -63.84% -36.77% 30.39%
Inventory
Prepaid Expenses
Receivables $0.00 $100.9K $205.9K
Other Receivables $16.21K $93.36K $79.43K
Total Short-Term Assets $455.2K $5.836M $14.41M $2.913M $1.814M $1.501M
YoY Change -92.2% -59.51% 394.87% 60.56% 20.86%
Property, Plant & Equipment $176.4K $79.84K $102.9K
YoY Change 120.88% -22.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $176.4K $79.85K $102.9K $0.00 $0.00 $0.00
YoY Change 120.85% -22.41%
Total Assets $631.6K $5.916M $14.52M $2.913M $1.814M $1.501M
YoY Change
Accounts Payable $2.925M $2.870M $1.163M $503.6K $929.6K $1.105M
YoY Change 1.91% 146.82% 130.91% -45.83% -15.84%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $300.7K $0.00 $0.00 $335.3K $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.226M $2.870M $1.165M $899.6K $992.3K $1.184M
YoY Change 12.39% 146.38% 29.49% -9.34% -16.19%
Long-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Total Liabilities $3.226M $2.870M $1.165M $899.6K $992.3K $1.184M
YoY Change 12.39% 146.38% 29.49% -9.34% -16.19%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2024 2023 2022 2021 2020 2019
Basic Shares Outstanding 676.6K shares 97.52M shares 89.10M shares 72.65M shares
Diluted Shares Outstanding 676.6K shares 97.52M shares 89.10M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $5.3257 Million

About Alzamend Neuro, Inc.

Alzamend Neuro Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Industry: Pharmaceutical Preparations Peers: Annovis Bio, Inc. Rezolute, Inc. ATOSSA THERAPEUTICS, INC. Candel Therapeutics, Inc. RENOVARO INC. Biostax Corp. Inozyme Pharma, Inc. MEDICINOVA INC